CA2491508A1 - Proteines hybrides de vhc a domaines ns3 modifies - Google Patents

Proteines hybrides de vhc a domaines ns3 modifies Download PDF

Info

Publication number
CA2491508A1
CA2491508A1 CA002491508A CA2491508A CA2491508A1 CA 2491508 A1 CA2491508 A1 CA 2491508A1 CA 002491508 A CA002491508 A CA 002491508A CA 2491508 A CA2491508 A CA 2491508A CA 2491508 A1 CA2491508 A1 CA 2491508A1
Authority
CA
Canada
Prior art keywords
polypeptide
ser
hcv
asp
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002491508A
Other languages
English (en)
Inventor
Michael Houghton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2491508A1 publication Critical patent/CA2491508A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne des protéines hybrides de VHC comprenant un domaine de protéase NS3 muté, fusionné au moins à un autre épitope de VHC dérivé d'une autre zone de la polyprotéine de VHC. Les fusions peuvent être utilisées dans des méthodes de stimulation d'une réponse immunitaire cellulaire au VHC, notamment dans l'activation de cellules T spécifiques au virus de l'hépatite C (VHC), comprenant des cellules CD4?+¿ et CD8?+¿. Cette méthode peut être utilisée dans des systèmes modèles pour développer des compositions immunogéniques spécifiques à VHC, ainsi que pour immuniser un mammifère contre le VHC.
CA002491508A 2002-07-02 2003-07-02 Proteines hybrides de vhc a domaines ns3 modifies Abandoned CA2491508A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US39369402P 2002-07-02 2002-07-02
US60/393,694 2002-07-02
US39451002P 2002-07-08 2002-07-08
US60/394,510 2002-07-08
PCT/US2003/020996 WO2004005473A2 (fr) 2002-07-02 2003-07-02 Proteines hybrides de vhc a domaines ns3 modifies

Publications (1)

Publication Number Publication Date
CA2491508A1 true CA2491508A1 (fr) 2004-01-15

Family

ID=30118384

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002491508A Abandoned CA2491508A1 (fr) 2002-07-02 2003-07-02 Proteines hybrides de vhc a domaines ns3 modifies

Country Status (8)

Country Link
EP (1) EP1539809A4 (fr)
JP (2) JP2005532064A (fr)
CN (1) CN1678630A (fr)
AU (1) AU2003248818A1 (fr)
CA (1) CA2491508A1 (fr)
PL (1) PL374349A1 (fr)
RU (1) RU2005102484A (fr)
WO (1) WO2004005473A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491808B2 (en) * 2000-06-15 2009-02-17 Novartis Vaccines And Diagnostics, Inc. HCV non-structural protein mutants and uses thereof
EP1576125A4 (fr) * 2002-10-25 2008-09-03 Novartis Vaccines & Diagnostic Activation de lymphocytes specifiques du vhc
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
CA2566725A1 (fr) * 2004-05-17 2005-12-01 Chiron Corporation Domaine ns5 du virus de l'hepatite c tronque et proteines hybrides comprenant ce dernier
WO2006024020A2 (fr) 2004-08-27 2006-03-02 Novartis Vaccines And Diagnostics Inc. Mutants de proteines non structurelles du vhc et leurs utilisations
AU2011254055B2 (en) * 2004-10-18 2012-12-20 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
WO2006044923A2 (fr) 2004-10-18 2006-04-27 Globeimmune, Inc. Moyens therapeutiques a base de levure contre l'infection par hepatite c chronique
WO2007031867A2 (fr) * 2005-05-25 2007-03-22 Tripep Ab Gene de fusion ns3/4a non structurel de l'hepatite c
CN101300355A (zh) * 2005-10-13 2008-11-05 威瑞克斯医药公司 包含丙型肝炎病毒多肽和用于引起免疫应答的Fc片段的嵌合抗原
GB0524408D0 (en) * 2005-11-30 2006-01-11 Glaxosmithkline Biolog Sa Vaccines
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
JP5474547B2 (ja) * 2006-08-25 2014-04-16 ノバルティス アーゲー Ｈｃｖ融合ポリペプチド
EP2331125A4 (fr) 2008-09-19 2013-03-27 Globeimmune Inc Immunothérapie pour infection chronique par le virus de l'hépatite c
WO2012038950A1 (fr) 2010-09-20 2012-03-29 Ramot At Tel-Aviv University Ltd. Complexes de toxine activables comprenant un peptide inhibiteur clivable
WO2016160046A1 (fr) * 2015-03-27 2016-10-06 Ortho-Clinical Diagnostics, Inc. Polypeptides ns4a/ns3 modifié du vhc et leurs utilisations
CN106749672B (zh) * 2016-11-18 2020-06-30 江西农业大学 一种丙型肝炎病毒融合抗原蛋白及其应用
CN111153963B (zh) * 2020-01-19 2021-08-10 华南理工大学 抗炎五肽及其提取分离方法和在改善记忆中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0992580T3 (da) * 1993-11-04 2005-07-11 Innogenetics Nv Epitoper på human T-celler, som er immundominante for hepatitis C-virus
KR100788812B1 (ko) * 1999-11-24 2007-12-27 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 신규한 ｈｃｖ 비구조 폴리펩티드
WO2001090812A1 (fr) * 2000-05-23 2001-11-29 Massachusetts Institute Of Technology Dispositifs non lineaires de fluorure ultraviolet

Also Published As

Publication number Publication date
EP1539809A2 (fr) 2005-06-15
JP2005532064A (ja) 2005-10-27
PL374349A1 (en) 2005-10-17
RU2005102484A (ru) 2006-01-20
JP2006265267A (ja) 2006-10-05
CN1678630A (zh) 2005-10-05
WO2004005473A3 (fr) 2004-04-01
EP1539809A4 (fr) 2006-03-08
AU2003248818A1 (en) 2004-01-23
WO2004005473A2 (fr) 2004-01-15

Similar Documents

Publication Publication Date Title
US6562346B1 (en) Activation of HCV-specific T cells
JP2006265267A (ja) 改変したｎｓ３ドメインを有するｈｃｖ融合タンパク質
US20100291134A1 (en) Truncated hepatitis c virus ns5 domain and fusion proteins comprising same
KR20020065537A (ko) 신규한 ｈｃｖ 비구조 폴리펩티드
US7439058B2 (en) HBV/HCV virus-like particle
US6986892B1 (en) Immunogenic Hepatitis C virus non-structural polypeptides
EP1233783B9 (fr) Particule de type virus hbv/hcv
US20050074465A1 (en) HCV fusion proteins with modified NS3 domains
JP2014036675A (ja) Ｈｃｖ融合ポリペプチド
CA2505611A1 (fr) Activation de lymphocytes specifiques du vhc
EP1535628B1 (fr) Particule de type virus hbv/hcv

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead